fluoxetine has been researched along with orlistat in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 11 (52.38) | 29.6817 |
| 2010's | 9 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Borrell, L; Foreyt, JP; Haddock, CK; Poston, WS | 1 |
| Czupryniak, L; Drzewoski, J | 1 |
| Sanders, TA; Taylor, D; Werneke, U | 1 |
| Kanitra, L; Moore, R; Mulligan, TE; Zhi, J | 1 |
| Avenell, A; Gregg, E; Kim, C; Lau, J; Norris, SL; Schmid, CH; Zhang, X | 1 |
| Li, Z; Maggard, M; Maglione, M; Mojica, WA; Morton, SC; Shekelle, PG; Shugarman, L; Solomon, V; Suttorp, M; Tu, W | 1 |
| Arterburn, D | 2 |
| Avenell, A; Gregg, E; Lau, J; Norris, SL; Schmid, CH; Zhang, X | 1 |
| Arterburn, D; DeLaet, D; Flum, D | 1 |
| Toubro, S | 1 |
| Al-Zaman, Y; Aylwin, S | 1 |
| Kachowski, L; Over, DR; Qiu, K | 1 |
| Bergström, E; Boxall, AB; Carter, LJ; Dowle, A; Garman, CD; Ryan, J; Thomas-Oates, J | 1 |
| Boxall, ABA; Carter, LJ; Ryan, JJ | 1 |
| Atkinson, G; Baur, L; Corpeleijn, E; Ells, LJ; Finer, N; Mead, E; Metzendorf, MI; O'Malley, C; Richter, B | 1 |
11 review(s) available for fluoxetine and orlistat
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Challenges in obesity management.
Topics: 1-Naphthylamine; Adrenergic beta-Agonists; Appetite Depressants; Behavior Therapy; Caffeine; Cyclobutanes; Diethylpropion; Ephedrine; Fenfluramine; Fluoxetine; Humans; Lactones; Leptin; Lipase; Obesity; Orlistat; Phentermine; Proteins; Sertraline | 1998 |
Options for pharmacological management of obesity in patients treated with atypical antipsychotics.
Topics: Amantadine; Antipsychotic Agents; Cimetidine; Cyclobutanes; Fluoxetine; Fructose; Humans; Lactones; Metformin; Nizatidine; Obesity; Orlistat; Topiramate; Weight Gain | 2002 |
Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis.
Topics: Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Drug Therapy; Female; Fluoxetine; Humans; Lactones; Male; Meta-Analysis as Topic; Middle Aged; Orlistat; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Weight Loss | 2004 |
Pharmacological and surgical treatment of obesity.
Topics: Adult; Appetite Depressants; Bupropion; Cyclobutanes; Diethylpropion; Fluoxetine; Fructose; Gastric Bypass; Gastroplasty; Humans; Lactones; Lipase; Obesity; Orlistat; Phentermine; Topiramate | 2004 |
Obesity.
Topics: Adult; Appetite Depressants; Cyclobutanes; Diethylpropion; Fluoxetine; Humans; Lactones; Mazindol; Obesity; Orlistat; Phentermine; Phenylpropanolamine | 2003 |
Obesity.
Topics: Adult; Appetite Depressants; Cyclobutanes; Diethylpropion; Fluoxetine; Humans; Lactones; Mazindol; Obesity; Orlistat; Phentermine; Phenylpropanolamine; Selective Serotonin Reuptake Inhibitors | 2004 |
Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Fluoxetine; Humans; Lactones; Obesity; Orlistat; Randomized Controlled Trials as Topic; Weight Loss | 2005 |
Obesity.
Topics: Adult; Appetite Depressants; Cyclobutanes; Diethylpropion; Fluoxetine; Gastric Bypass; Gastroplasty; Humans; Lactones; Mazindol; Obesity; Orlistat; Phentermine | 2005 |
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Bariatric Surgery; Body Mass Index; Bupropion; Cholecystokinin; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Cyclobutanes; Depression; Diabetes Mellitus, Type 2; Female; Fluoxetine; Fructose; Ghrelin; Humans; Intra-Abdominal Fat; Islet Amyloid Polypeptide; Isoxazoles; Lactones; Leptin; Metabolic Syndrome; Metformin; Obesity; Obesity, Morbid; Orlistat; Oxyntomodulin; Peptide YY; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Sertraline; Sleep Apnea, Obstructive; Surgical Procedures, Operative; Topiramate; Zonisamide | 2008 |
Drug interventions for the treatment of obesity in children and adolescents.
Topics: Adolescent; Anti-Obesity Agents; Body Mass Index; Child; Cyclobutanes; Fluoxetine; Humans; Lactones; Metformin; Orlistat; Pediatric Obesity; Randomized Controlled Trials as Topic | 2016 |
1 trial(s) available for fluoxetine and orlistat
| Article | Year |
|---|---|
Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Antidepressive Agents, Second-Generation; Area Under Curve; Cross-Over Studies; Double-Blind Method; Drug Interactions; Female; Fluoxetine; Gas Chromatography-Mass Spectrometry; Half-Life; Humans; Hypolipidemic Agents; Lactones; Lipase; Male; Middle Aged; Orlistat; Simvastatin | 2003 |
9 other study(ies) available for fluoxetine and orlistat
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
[The role of pharmacotherapy for treatment of obesity in adults].
Topics: Adult; Animals; Anti-Obesity Agents; Chlorphentermine; Cyclobutanes; Dexfenfluramine; Dopamine Agonists; Ephedrine; Fluoxetine; Humans; Lactones; Mazindol; Obesity; Orlistat | 2000 |
[Pharmacotherapy for weight loss in patients with type 2 diabetes].
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Fluoxetine; Follow-Up Studies; Humans; Lactones; Obesity; Orlistat; Randomized Controlled Trials as Topic; Risk Factors; Weight Loss | 2007 |
FPIN’s clinical inquiries. Medications for weight loss in patients with type 2 diabetes mellitus.
Topics: Anti-Obesity Agents; Cyclobutanes; Diabetes Mellitus, Type 2; Fluoxetine; Fructose; Humans; Lactones; Orlistat; Selective Serotonin Reuptake Inhibitors; Topiramate | 2012 |
Fate and uptake of pharmaceuticals in soil-earthworm systems.
Topics: Adsorption; Animals; Biodegradation, Environmental; Carbamazepine; Diclofenac; Fluoxetine; Lactones; Models, Biological; Oligochaeta; Orlistat; Pharmaceutical Preparations; Porosity; Quantitative Structure-Activity Relationship; Soil; Time Factors; Water | 2014 |
Effects of soil properties on the uptake of pharmaceuticals into earthworms.
Topics: Animals; Carbamazepine; Diclofenac; Fluoxetine; Hydrogen-Ion Concentration; Lactones; Oligochaeta; Orlistat; Pharmaceutical Preparations; Soil; Soil Pollutants; Water | 2016 |